Drugs that contain Vibegron
1. Drug name - GEMTESA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8653260 | UROVANT | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(6 years from now) | |
| US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(8 years from now) | |
| CN102391255B | UROVANT | Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| CN102056917A | UROVANT | Hydroxymethyl Pyrrolidines As [Beta]3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| CN102056917B | UROVANT | Hydroxymethyl Pyrrolidine As 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| CN102391255A | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonist |
Apr, 2029
(6 years from now) | |
| IN281652B | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| IN201005984P4 | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| EP2276756A1 | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| EP2276756B1 | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| EP2276756B9 | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
| EP2276756B8 | UROVANT | Hydroxymethyl Pyrrolidines As Beta 3 Adrenergic Receptor Agonists |
Apr, 2029
(6 years from now) | |
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 75MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.